New York Valves 2025: 4 Trials Under Discussion
• EARLY TAVR
• Redo TAVR and TAVR Explant
• TRILUMINATE
• Intrepid TMVR Early Feasibility Study
• EARLY TAVR
• Redo TAVR and TAVR Explant
• TRILUMINATE
• Intrepid TMVR Early Feasibility Study
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Cath Lab Digest or HMP Global, their employees, and affiliates.
Bailey Estes, MSN, AGNP, RN-BC, RNFA, CNOR, RCIS1, talks with
Ahmad Alkhalil, MD, MSc2
1Interventional Cardiology Nurse Practitioner, Alleviant Medical, Austin, Texas;
2Assistant Professor of Medicine; Director, Mitral and Tricuspid Interventions, Stony Brook University Hospital; Director, Cath Lab, Northport VA Hospital, Stony Brook, New York
Listen in as Interventional Cardiology Nurse Practitioner Bailey Estes talks with Dr. Ahmad Alkhalil about four presented trials that were hotly anticipated at the CRF New York Valves Meeting, held June 24-26, 2025, in New York:
• EARLY TAVR (@ 00:40 sec mark)
• Redo TAVR and TAVR Explant (@ 9:00 min mark)
• TRILUMINATE (@ 15:12 min mark)
• Intrepid TMVR Early Feasibility Study (@ 27:03 min mark)
Click on each trial title below to find the original NYV presentations:
Presented at New York Valves by Drs. Allan Schwartz, Martin Leon & Philippe Généreux, on behalf of the EARLY TAVR Investigators
• TAVR Reintervention Strategies: Unveiling Trends and Outcomes of Redo TAVR and TAVR Explant
Presented at New York Valves by Shinichi Fukuhara, MD
• Clinical Progression in the TRILUMINATE Pivotal Control Patients: The TRILUMINATE Pivotal Trial
Presented at New York Valves by Matthew J. Price, MD, on behalf of the TRILUMINATE Pivotal Investigators
Presented at New York Valves by Gilbert H.L. Tang, MD, MSc, MBA, on behalf of the Intrepid TMVR Early Feasibility Study Clinical Investigators
